南方医科大学学报 ›› 2021, Vol. 41 ›› Issue (2): 173-183.doi: 10.12122/j.issn.1673-4254.2021.02.03

• • 上一篇    下一篇

含瓜蒌方剂的组方规律及核心药对“瓜蒌-甘草”的作用机制: 基于网络药理学和分子对接技术

鄢海燕, 邹纯才   

  • 发布日期:2021-02-05

Use of Trichosanthis fructus and the core drug pair Trichosanthis fructus-Glycyrrhizae radix et rhizoma in traditional Chinese prescriptions: molecular mechanisms in network pharmacology and molecular docking

  • Published:2021-02-05

摘要:

目的 利用中医古籍知识库对含瓜蒌方剂的组方规律进行分析,验证所获得的核心药对“瓜蒌-甘草”在治疗痰证类疾病方面的分子机制。方法 采用Matlab语言,以某种(类)疾病出现频次累积量占所有种(类)疾病出现频次累积量百分比计,对中医古籍知识库中含瓜蒌方剂进行治疗疾病及配伍统计分析。运用TCMSP数据库,以“瓜蒌”、“甘草”分别检索瓜蒌、甘草的化学成分,选择符合口服生物利用度≥30%、类药性≥0.18的化学成分并导入SwissTargetPrediction数据库,检索符合Probability≥0.1的化学成分靶点蛋白。运用CooLGeN、GeneCards数据库,以“Phlegm syndrome”(痰证)为关键词收集疾病(人类基因)靶点蛋白。筛选化学成分与疾病共有靶点蛋白,通过DAVID数据库,选择KEGG_PATHWAY通路及其涉及的靶点蛋白、化学成分,构建化学成分-靶点蛋白-信号通路网络,对“瓜蒌-甘草”治疗痰证类疾病的分子机制进行研究并采用分子对接技术进行验证。结果 在中医古籍知识库中收载1700个含瓜蒌方剂,主要用于28种(类)疾病的治疗。在含瓜蒌方剂中,有11种(类)疾病出现频次累积量占所有种(类)疾病出现频次累积量百分比达3%以上,痰证类居首,为14.0%。在含瓜蒌方剂核心药对中,“瓜蒌-甘草”药对出现频次累积量最高且用于痰证类疾病治疗的出现频次累积量较高,达113次。在化学成分-靶点蛋白-信号通路网络中,“瓜蒌-甘草”药对共有52个化学成分(瓜蒌9个,甘草43个)与痰证类疾病相关,这些成分利用PPARD、NLRP3、PPARG、MMP9、CCND1等41个靶点蛋白通过Pathways in cancer、NOD-like receptor signaling pathway等信号通路发挥治疗痰证类相关疾病的作用。分子对接结果显示,40 个化学成分与 10 个靶点蛋白分子对接的 Total Score 值大于 5,其中 MOL001494、MOL007179 与PPARD、PPARG靶点蛋白分子对接的Total Score值大于10。结论 含瓜蒌方剂的用药规律可循,通过不同配伍达到不同的治疗目的。“瓜蒌-甘草”配伍可能通过调控Pathways in cancer、NOD-like receptor signaling pathway等信号通路,影响PPARD、NLRP3等的表达,干预细胞增殖、细胞凋亡等多个生物学过程,发挥治疗“痰证类”疾病作用。

关键词:

Abstract:

Objective To analyze the rationale for use of Trichosanthis fructus in traditional Chinese prescriptions and explore the
molecular mechanism of the core drug pair Trichosanthis fructus-Glycyrrhizae radix et rhizoma for treatment of phlegm syndrome diseases. Methods We analyzed the cumulative frequency of the use of Trichosanthis fructus in traditional Chinese prescriptions and the disease spectrum treated using the prescriptions containing Trichosanthis fructus. We searched TCMSP database for the chemical components of Trichosanthis fructus and Glycyrrhizae radix et rhizoma and explored their target proteins using Swiss Target Prediction database. We also searched the CooLGeN and GeneCards databases for the potential disease target proteins using the key words "phlegm syndrome". The chemical component-target protein-signal pathway network was constructed using DAVID database to analyze the molecular mechanism of Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair for treatment of phlegm syndrome diseases, and the result was verified by molecular docking technology. Results A total of 1700 prescriptions containing Trichosanthis fructus were retrieved, which were used for treatment of 28 diseases. Phlegm syndrome was the most frequent among the 28 diseases (14.0% ). The Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair had a cumulative frequency of 113 for use in treatment of phlegm diseases, and was the core drug pair in prescriptions containing Trichosanthis fructus. Fifty-two chemical components related to phlegm syndrome diseases were identified in the drug pair (9 in Trichosanthis fructus and 43 in Glycyrrhizae radix et rhizoma), and their therapeutic effects were mediated by a total of 41 target proteins involving the cancer pathway, NOD-like receptor signaling pathway and another 17 signal pathways. The results of molecular docking showed that 40 chemical components docking with 10 target protein molecules had total scores greater than 5. Conclusion The different formulations of Trichosanthis fructus containing prescriptions serve different therapeutic purposes. The mechanisms of the Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair for treatment of phlegm syndrome diseases involve multiple pathways for regulating cell proliferation, apoptosis and other biological processes.

Key words: